What is NCT00003702, and what does it test?
NCT00003702 is a clinical trial record associated with methotrexate, but the question “methotrexate more effective” depends on what comparison the study used (for example, methotrexate vs placebo, vs another regimen, or different dosing schedules). With only the trial ID provided, there isn’t enough information here to determine whether methotrexate was more effective than the comparator and for which outcome (tumor response, symptom improvement, survival, flare rates, etc.).
Was methotrexate shown to be more effective in NCT00003702?
To answer that directly, you need two details from the trial record:
1) the study’s primary endpoint (the main outcome it measured), and
2) the comparator arm(s) (what methotrexate was being compared against).
“More effective” can mean different things depending on the endpoint—such as higher response rates, longer time to progression, fewer relapses, or better functional outcomes.
How to check effectiveness quickly (what to look for in the results)
If you pull up NCT00003702, the key places to look are:
- “Primary Outcome Measures” and the reported results for that endpoint.
- The statistical comparison between arms (p-values and effect size, if provided).
- Whether the trial reports “results” at all, and whether it’s completed with published data or only posted data.
If the trial didn’t publish results, can we still tell?
If the trial record does not list results, effectiveness can’t be confirmed from the ID alone. In that case, you can only say what the trial was designed to test, not whether it worked.
Next step: share what you see in the trial record
If you paste the following from NCT00003702 (even just a few lines), I can tell you whether methotrexate was more effective and how that conclusion is supported:
- primary endpoint / outcome measure(s)
- the study arms (methotrexate vs what?)
- any outcome numbers or the “Results” section text
Sources
No sources were provided with the trial ID, and none were available in the prompt to cite.